An Equation to Estimate the Concentration of Serum Apolipoprotein B

被引:13
作者
Hwang, You-Cheol [2 ]
Ahn, Hong-Yup [3 ]
Lee, Woo Je [4 ]
Park, Cheol-Young [1 ]
Park, Sung-Woo [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab,Kangbuk Samsung Hosp, Seoul, South Korea
[2] Kyung Hee Univ, Div Endocrinol & Metab, Dept Med, Sch Med,Kyung Hee Univ Hosp Gangdong, Seoul, South Korea
[3] Dongguk Univ Seoul, Dept Stat, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Dept Internal Med, Asan Med Ctr, Seoul, South Korea
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; MYOCARDIAL-INFARCTION; RISK; MANAGEMENT; DISEASE; EVENTS; PLASMA; LIPIDS;
D O I
10.1371/journal.pone.0051607
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Several large prospective studies have demonstrated that apolipoprotein B (apoB) has greater value in predicting cardiovascular risk than any other lipid measurements. Currently, however, serum apoB levels are not routinely measured, because of the additional cost. The aim of this study was to develop an equation to estimate apoB from conventional lipid measurements including total cholesterol, HDL cholesterol, and triglycerides. Methods: Data from a total of 78,127 subjects (47,057 men and 31,070 women), aged 15 to 88 years (mean age 41.8 years) were reviewed to develop an apoB equation. Additional datasets from the same institution and the NHANES obtained in 2007-2008 were used for internal (n = 73,445) and external validation (n = 3,097), respectively. Results: We developed an apoB equation based on a linear regression model that contains total cholesterol, triglycerides, and HDL cholesterol as terms (model 1). To more precisely estimate the serum apoB level, we adjusted mode1 1 using a cutoff serum triglyceride value of 270 mg/dl (model 2). Model 2 showed more randomly distributed residuals in patients with diabetes, atherogenic dyslipidemia, and those taking lipid-lowering agents than model 1. The residuals in the development, internal validation, and external validation datasets were also randomly distributed around 0 with no clear trends. Conclusion: The new equation we developed to estimate serum apoB concentrations is accurate and can be used in diverse subgroups of patients including those with diabetes, atherogenic dyslipidemia, and those taking lipid-lowering agents.
引用
收藏
页数:7
相关论文
共 15 条
[2]   Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel [J].
Barter, PJ ;
Ballantyne, CM ;
Carmena, R ;
Cabezas, MC ;
Chapman, MJ ;
Couture, P ;
De Graaf, J ;
Durrington, PN ;
Faergeman, O ;
Frohlich, J ;
Furberg, CD ;
Gagne, C ;
Haffner, SM ;
Humphries, SE ;
Jungner, I ;
Krauss, RM ;
Kwiterovich, P ;
Marcovina, S ;
Packard, CJ ;
Pearson, TA ;
Reddy, KS ;
Rosenson, R ;
Sarrafzadegan, N ;
Sniderman, AD ;
Stalenhoef, AF ;
Stein, E ;
Talmud, PJ ;
Tonkin, AM ;
Walldius, G ;
Williams, KMS .
JOURNAL OF INTERNAL MEDICINE, 2006, 259 (03) :247-258
[3]   Lipoprotein management in patients with cardiometabolic risk [J].
Brunzell, John D. ;
Davidson, Michael ;
Furberg, Curt D. ;
Goldberg, Ronald B. ;
Howard, Barbara V. ;
Stein, James H. ;
Witztum, Joseph L. .
DIABETES CARE, 2008, 31 (04) :811-822
[4]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[5]   Estimation of ten-year risk of fatal cardiovascular disease in Europe:: the SCORE project [J].
Conroy, RM ;
Pyörälä, K ;
Fitzgerald, AP ;
Sans, S ;
Menotti, A ;
De Backer, G ;
De Bacquer, D ;
Ducimetière, P ;
Jousilahti, P ;
Keil, U ;
Njolstad, I ;
Oganov, RG ;
Thomsen, T ;
Tunstall-Pedoe, H ;
Tverdal, A ;
Wedel, H ;
Whincup, P ;
Wilhelmsen, L ;
Graham, IM .
EUROPEAN HEART JOURNAL, 2003, 24 (11) :987-1003
[6]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[7]   Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) [J].
Gotto, AM ;
Whitney, E ;
Stein, EA ;
Shapiro, DR ;
Clearfield, M ;
Weis, S ;
Jou, JY ;
Langendörfer, A ;
Beere, A ;
Watson, DJ ;
Downs, JR ;
de Cani, JS .
CIRCULATION, 2000, 101 (05) :477-484
[8]   Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment [J].
Kastelein, John J. P. ;
van der Steeg, Wim A. ;
Holme, Ingar ;
Gaffney, Michael ;
Cater, Nilo B. ;
Barter, Philip ;
Deedwania, Prakash ;
Olsson, Anders G. ;
Boekholdt, S. Matthijs ;
Demicco, David A. ;
Szarek, Michael ;
LaRosa, John C. ;
Pedersen, Terje R. ;
Grundy, Scott M. .
CIRCULATION, 2008, 117 (23) :3002-3009
[9]   Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels [J].
Marcovina, S ;
Packard, CJ .
JOURNAL OF INTERNAL MEDICINE, 2006, 259 (05) :437-446
[10]  
MCNAMARA JR, 1990, CLIN CHEM, V36, P36